Introduction to targeted drugs: CLL/SLL is... - CLL Support

CLL Support

23,339 members40,047 posts

Introduction to targeted drugs

HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin
0 Replies

CLL/SLL is classified as a type of NHL by the World Health Organisation. This is an interesting article written by Karl Schwartz of Lymphomation.org it may aid your understanding of targeted drugs. This is an easy understand overview of the topic. remember some of the drug listed are not for CLL/SLL .

Introduction to targeted drugs for Lymphoma

lymphomation.org/agents.htm...

intro posted in Yahoo groups, forwarded with Karl's consent:

intro: targeted drugs for Lymphoma ... what's a pathway?

Targeted drugs might be defined as compounds (chemical or proteins)

that bind to a part of a tumor cells in order to have an anti-cancer effect.

Our goal is to foster a general understanding of how the novel targeted

agents for lymphoma are thought to work - as an aid to informed consent.

Targeted drugs to treat cancer work in many different ways - commonly by

interfering with a pathway that supports the growth or persistence of the

abnormal cells. A pathway is like a system in an automobile that controls

how the car works ...

Lymphomation. org: lymphomation.org/agents.htm...

(with links to trials for targeted agents)

Bcc: advisors for guidance as always.

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Written by
HAIRBEAR_UK profile image
HAIRBEAR_UK
Founder Admin
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Zanubrutinib-Gazyva Shows Promise for CLL/SLL

June 25, 2019 Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s...
Jm954 profile image
Administrator

CLL INFORMATION - A developing reliable and current international list of CLL Information & Resources.

We have opened a thread that provides access to many of the key reliable UK and international...
HAIRBEAR_UK profile image
Founder Admin

Acalabrutinib Plus Obinutuzumab Prolongs Progression Free Survival Compared to Other Targeted Agents in Chronic Lymphocytic Leukaemia (CLL)

First-line acalabrutinib plus obinutuzumab prolongs progression-free survival (PFS) compared to...
AussieNeil profile image
Partner

CLL Society interview - Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Patients with CLL/SLL January 13, 2023

Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Patients with CLL/SLL January 13,...
lankisterguy profile image
Volunteer

ASH 2019: A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

"Conclusion: This study demonstrates that it is safe to administrate a single dose of Sativex to...
avzuclav profile image